Date: April 15, 2022 | 3:00 – 4:30 PM IST
The Covid-19 crisis has spurred innovation and discoveries across the pharma space. Indian companies have demonstrated that they can deliver when the country is faced with a crisis. Many companies in the pharmaceutical and healthcare sectors have ramped up production and invested in R & D. The development of Covaxin by Bharat Biotech was the highlight of 2021.
According to an OECD estimate, the pharmaceutical industry in India is expected to grow by 317 percent between 2017 and 2060. Currently, over 50 percent of the world’s demand for vaccines, 40 percent of the demand for generic drugs in the United States, and one-fourth of all medicine demand in the United Kingdom is supplied by the Indian pharmaceutical industry.
However, Indian pharmaceutical companies spend 8-13 percent of their total turnover on R&D. Various reports suggest that R&D spending moderated to 8.8 percent during FY18 and further to 7.8 percent in FY19. The aggregate R&D spending of the top few domestic companies further moderated to 6.9 percent in Q1FY20.
ICRA expects the R&D expenses to stabilize at current levels and remain in the range of 6.5%-7.5% as companies continue to focus on complex generics, first-to-file opportunities, specialty products that entail higher R&D expenses. Stable investments in R&D to develop such products will support growth and margin improvement over the medium term.
Hence, it has become more important for India’s pharma R&D to evolve and become more agile and responsive with the help of technology and differentiated strategies to embark on the next phase of growth. The R&D sector will have to reorient its strategies and redraw its approaches to give a much needed push to the industry. Here, the role of digital and automation technologies will have to play a prominent role by harnessing the potential value of emerging technologies such as AI, Analytics, and automation.
Key discussion points:
- Emerging R&D scenario in pharma sector globally and in India
- Need to build an efficient and agile operating model by embracing new technologies
- Adopting innovative R&D models
- Co-opetition is the way forward
- Digitisation of labs for quality and compliance
- GLP and R&D
- Outsourcing R&D
Severity: Warning
Message: count(): Parameter must be an array or an object that implements Countable
Filename: views/webinar-details-new.php
Line Number: 220
Backtrace:
File: /data/httpd_data/itrusoft/indianpharmapost.com/htdocs/application/views/webinar-details-new.php
Line: 220
Function: _error_handler
File: /data/httpd_data/itrusoft/indianpharmapost.com/htdocs/application/controllers/Webinar.php
Line: 270
Function: view
File: /data/httpd_data/itrusoft/indianpharmapost.com/htdocs/index.php
Line: 329
Function: require_once
Dr. Mukund Chorghade is a serial entrepreneur and Founder, President and Chief Scientific Officer, THINQ Pharma and Ayurvidya Healthcare Innovations. He is the CSO of APINOVO. He was awarded a D.Sc. by the University of Mumbai in 2021. He provides synthetic chemistry, process and pharmaceutical development expertise to academic laboratories, pharmaceutical and biopharmaceutical companies, and engineers strategic collaborations between them. His research interests are in Drug Discovery and Development, Process Chemistry Derived Medicinal Chemistry, Traditional Indian and Chinese Medicine.
Ravikumar Nithiyanandam is the Executive Vice President—Formulations R&D at MSN Laboratories, Hyderabad. He has proven abilities in leadership combined with a remarkable track record of delivering multiple high-value projects to the market.
He has over 29 years of experience in pharmaceutical formulations R&D. He has been associated with companies viz. Ranbaxy, Apotex, Amneal and Jubilant in various leadership roles. Instrumental in submitting over 160+ ANDAs in the US market and a number of submissions in the rest of the geographies out of which a good number of products have been approved and commercialized. He has over 20 plus patents to his name.
ManiKandan Ramalingam is pharmaceutical technologist with 22 years of experience and holds M. Pharma Tech from NIPER (Mohali) and Master black belt in six sigma. In his experience, worked in providing technical, strategic, and functional leadership in uniquely challenging positions in Pharmaceutical Research. Worked at Sun Pharma and Dr. Reddy’s prior to joining Granules; and served as functional head of Product development Research and subject matter expert for formulation at Dr.Reddys. Has expertise in, API Assessment for FD design & API – FD integration, Pre-formulation, Formulation design. (Different type of dosage forms), Biopharmaceutics and pharmacokinetics, New Technology adoption and Product Scale up and manufacturing. Also served in leading cross functional research team, change management, Training and team building, Regulatory risk management, product selection assessment, Contract research management, thereby ensuring successful translation of products from Ideation to the Market.
Kinjal Shah is Vice President and Co-Group Head – Corporate Ratings and a member of the Rating Committee of ICRA Limited. She joined ICRA Limited in 2008 and has been a part of the Corporate Ratings team since then, working on multiple rating assignments across various sectors, which include among others, Pharmaceuticals, Auto, Healthcare, Aviation, IT Services, FMCG and Holdcos.
Kinjal holds a Bachelor’s Degree in Management Studies from Narsee Monjee College of Commerce & Economics, University of Mumbai, and Masters in Business Administration from Narsee Monjee Institute of Management Studies. She has also completed CFA from the CFA Institute, USA.
Gaurav Kaushik is the Managing Director & CEO of Meteoric Biopharmaceuticals. A first-generation entrepreneur and a gold medallist in biotechnology, Meteoric is a leading name in the biopharma landscape with over 100 products across Enzymes & Enzymatic Preparations, Probiotics, Nutraceuticals and Animal Healthcare. The company has always delivered the highest quality products backed by sound technical support. Product customization and concept formulation have been the core strength of the company.
Gaurav has been awarded the Rashtriya Udyog Ratan Award by the Council of Economic Growth & Research, in 2010. He is also the recipient of the Indian Leadership Award for Industrial Development by All India Achievers Foundation, 2011.
Meteroric today exports its products across 50 countries and has registered its first Probiotic Patent BCM – 9, MTCC No. 25157.
Rajeev brings solid and diverse global expertise and experience working for transnational companies in India, the USA, the Middle East, and the U.K. across Energy, Manufacturing & Consulting. He has built a reputation of leading organizational transformation and as a progressive H.R. practitioner.
He has joined Solara from ATC Tires where he was the CHRO and CSR Head, responsible for Human Resource strategy and operations globally. Before ATC, he held the position of President & Global CHRO for Welspun Corp.
Rajeev started his career in Industrial Relations with Bharat Petroleum, Mumbai Refinery before moving to work with PwC, India, and in various leadership roles with B.G. Group (now Shell) in the UK, India, and the Middle East.
